Alnylam price target raised to $450 from $325 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Alnylam (ALNY) to $450 from $325 and keeps an Overweight rating on the shares. Focus is on Amvuttra’s Q3 results after a strong $150M debut in ATTR-CM last quarter, with expectations now above $300M, the analyst tells investors in a research note. Alnylam continues to execute well on the cardiomyopathy launch, and signs point to sustained commercial momentum through the second half of 2025, the firm says.